ACM
CLLS

Apex Capital Management’s Cellectis CLLS Stock Holding History

Apex Capital Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$254K Buy
+9,229
New +$222K 0.01% 258

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
THSP
Taube Hodson Stonex Partners London, United Kingdom $488M AUM 4.7% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Apex Capital Management's CLLS Position: Q1 2016 in Review

Apex Capital Management opened a new position in Cellectis (CLLS) in Q1 2016: 9,229 shares worth $254K. The stake represents 0.01% of the portfolio and ranks #258 among its holdings.

44 funds tracked by Wall St. Rank hold CLLS as of Q1 2016.

  • Apex Capital Management held 9,229 shares of Cellectis worth $254K as of Q1 2016.
  • Cellectis was a new Apex Capital Management position in Q1 2016.
  • Cellectis made up 0.01% of Apex Capital Management's portfolio in Q1 2016, its #258 holding.
  • 44 funds tracked by Wall St. Rank held Cellectis as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.